tradingkey.logo

Neogenomics Inc

NEO
View Detailed Chart
12.280USD
-0.020-0.16%
Close 12/26, 16:00ETQuotes delayed by 15 min
1.58BMarket Cap
LossP/E TTM

Neogenomics Inc

12.280
-0.020-0.16%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.16%

5 Days

+3.80%

1 Month

+1.24%

6 Months

+71.51%

Year to Date

-25.49%

1 Year

-28.94%

View Detailed Chart

TradingKey Stock Score of Neogenomics Inc

Currency: USD Updated: 2025-12-26

Key Insights

Neogenomics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 33/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.33.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neogenomics Inc's Score

Industry at a Glance

Industry Ranking
33 / 78
Overall Ranking
154 / 4563
Industry
Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 14 analysts
Buy
Current Rating
12.333
Target Price
+5.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neogenomics Inc Highlights

StrengthsRisks
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 29.59% year-on-year.
Overvalued
The company’s latest PE is -13.84, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 127.88M shares, decreasing 7.11% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 434.19K shares of this stock.

Neogenomics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Neogenomics Inc Info

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Ticker SymbolNEO
CompanyNeogenomics Inc
CEOZook (Antony P)
Websitehttps://neogenomics.com/

FAQs

What is the current price of Neogenomics Inc (NEO)?

The current price of Neogenomics Inc (NEO) is 12.280.

What is the symbol of Neogenomics Inc?

The ticker symbol of Neogenomics Inc is NEO.

What is the 52-week high of Neogenomics Inc?

The 52-week high of Neogenomics Inc is 19.115.

What is the 52-week low of Neogenomics Inc?

The 52-week low of Neogenomics Inc is 4.720.

What is the market capitalization of Neogenomics Inc?

The market capitalization of Neogenomics Inc is 1.58B.

What is the net income of Neogenomics Inc?

The net income of Neogenomics Inc is -78.73M.

Is Neogenomics Inc (NEO) currently rated as Buy, Hold, or Sell?

According to analysts, Neogenomics Inc (NEO) has an overall rating of Buy, with a price target of 12.333.

What is the Earnings Per Share (EPS TTM) of Neogenomics Inc (NEO)?

The Earnings Per Share (EPS TTM) of Neogenomics Inc (NEO) is -0.888.
KeyAI